Sumit Kumar

Chief Commercial Officer

The global pharmaceutical outsourcing market stands at nearly 250 billion US dollars, with India holding less than 5 percent share, signaling strong growth potential. Large pharma companies are increas ing outsourcing while prioritizing supply chain resilience through a China-plus-one diversification strategy. More over, India’s strong base of US FDA-approved facilities and global regulatory expertise enhance its credibility. ESG compliance, digitization, lifecycle support, cybersecurity, and data protection now influence partner selection.

However, the Indian CDMO space remains highly competitive, especially in small molecules. Rising regulatory complexity, dependence on China for key materials, digital investment needs, and macroeconomic volatility continue to challenge the industry.

Within this evolving landscape, Sekhmet Pharmaventures positions itself as a capability-driven, long-term CDMO partner. The group deepens engagement not only with existing big pharma clients by expanding portfolios and improving RFQ conversion through strong cross-functional execution, but also aggressively working to on-board new big pharma customers. Through this integrated approach, the group reinforces customer loyalty while steadily expanding its market presence in a competitive global environment.

Foundation of Excellence

Since its inception, the group anchored its strategy in deep chemistry expertise through its group companies Anjan Drug, Optimus Drugs and Optimus Pharma. Sekhmet follows a very focused approach towards its portfolio, developing breakthrough chemistry, building scale, and pursuing backward integration to create strong cost structures while ensuring better regulatory compliance and support. Notably, the company scaled manufacturing of key starting materials and drove high-volume API production.

Long before ESG became a mainstream, leadership embedded green chemistry into core operations. Teams replaced conventional solvents with water wherever feasible and adopted water-based reactions across processes. This blend of scale, regulatory compliance, cost competitiveness, and sustainability earned the trust of innovators and large pharmaceutical companies and helped the business secure meaningful market share.

Within the broader ecosystem, Optimus evolved as a hub of R&D agility. It gained recognition for rapid product development and accelerated launches. The company filed more than 300 patents and secured over 170 grants, underscoring its innovation depth. Together, Anjan and Optimus operate under the umbrella of Sekhmet Pharmaventures, combining deep chemistry and scale advantages with research agility and innovation strength.

“For over a decade, we have built enduring global big pharma partnerships, backed by nearly 250 scientists, reinvesting over 12 percent of revenue into R&D while continuing significant capital expansion in APIs, Intermediates, and key starting materials,” states Sumit Kumar, Chief Commercial Officer at Sekhmet Pharmaventures. ESG remains integral to its philosophy. Furthermore, the group holds an EcoVadis Bronze rating with a score of 69 and targets gold status. It has reduced Scope 2 emissions by over 52 percent in four years and positively impacted more than 100,000 people through CSR initiatives.

End-to-End Pharma Power

Sekhmet manages a portfolio of more than 60 products. It handles diverse and complex reactions at commercial and large scale. This capability provides structural advantage. The team integrates deeply backward into each product and builds strength across key process stages. This approach enhances supply chain robustness and reduces exposure to volatility. It also builds strong customer confidence.

Notably, the group maintains strict process discipline to deliver competitive cost structures and consistent value. It houses R&D, analytical, quality, and regulatory functions under one roof. This integrated structure enables faster development cycles and quicker turnaround. Scientists also optimize particle size and flowability to support seamless downstream manufacturing.

In addition, contract manufacturing forms the backbone of its services. The group supplies APIs, Intermediates, and Finished Dosage Formulations from facilities approved by the US FDA and compliant with European GMP standards. Its Formulations division offers a wide range of dosage forms, along with flexible packaging solutions to meet diverse market requirements and support large global pharmaceutical clients.

In parallel, the group supports customers from early development to commercialization. It works closely with innovators and large pharmaceutical companies. As part of life cycle management strategies, many such companies outsource APIs and intermediates. The group positions itself as a credible partner in this transition. It absorbs and optimizes transferred processes. It undertakes method development, verification, and regulatory alignment to meet stringent compliance standards. Through this integrated approach, the group supports clients across the full value chain.

Smart Edge

They closely engage with large pharmaceutical companies and innovator firms to address their specific requirement of the value chain and establish long term collaboration. Leadership also engages proactively with partners to identify emerging opportunities. R&D forms the core of the business model. The team collaborates closely with regulatory, analytical, operations, and supply chain teams to design scalable solutions. This coordinated structure accelerates problem solving and enhances value delivery while research plays a central role in identifying industry gaps and converting them into viable commercial opportunities.

The Path Ahead

Sekhmet operates 1,250 KL of manufacturing capacity and continues targeted CapEx expansion. It looks to strengthen backward integration and build alternate raw material sourcing in India and non-Chinese markets while maintaining selective China engagement to enhance supply security. Additionally, the group sustains a strong GMP compliance record and invests in quality and operational robustness.

Commercially, it expands within existing accounts, deepens engagement with new customers and global CDMOs, and aligns infrastructure, R&D, and efficiency initiatives to capture growth, positioning itself at a strategic inflection point for long-term expansion.